权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Prostate Cancer: Targeting Androgen Receptor Signaling by Tetrandrine

前列腺癌：粉防己碱靶向雄激素受体信号传导

基本信息

批准号：
8142602
负责人：
HARI K KOUL
金额：
--
依托单位：
VA EASTERN COLORADO HEALTH CARE SYSTEM
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-07-01 至 2015-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8142602
关键词：
Address Androgen Receptor Androgens Apoptosis Apoptotic Biological Models CDKN1A gene Cancer Cell Growth Cancer Etiology Cancer Model Cell Cycle Arrest Cell Cycle Inhibition Cell Cycle Progression Cell Death Cell Survival Cell physiology Cells Cessation of life Data Development Diagnosis Event Exhibits Growth Health Health education Human LNCaP Libraries Malignant - descriptor Malignant Neoplasms Malignant neoplasm of prostate Measures Mediating Messenger RNA Molecular Mus Neoplastic Processes Normal Cell Pathway interactions Phenotype Play Population Prevention Prostate Cancer therapy Prostate-Specific Antigen Proteins Receptor Signaling Regulation Resistance Role Screening procedure Signal Transduction Stephania tetrandra Testing Translating Tumor Volume United States Veterans Work Xenograft Model Xenograft procedure base cancer cell cancer diagnosis cell motility deprivation effective therapy efficacy testing in vivo inhibitor/antagonist killings men novel pre-clinical pre-clinical research prevent promoter receptor binding research study response tumor progression

项目摘要

DESCRIPTION (provided by applicant): Development of prostate cancer (PCa) and malignant progression requires altered regulation of many cellular processes, which are probably interrelated, including androgen receptor (AR) signaling, loss of growth control, and protection from apoptosis. Altered AR signaling is known to play a major role in progression of PCa to Castrate resistant phenotype. While screening for natural compounds for effects against prostate cancer cell growth, we found tetrandrine (Tet) to have selective effects against AR positive PCa cells. Tetrandrine (Tet), an active ingredient isolated from Stephania tetrandra is known to exhibit a broad range of pharmacological actions, and we are the first group to observe its effects against prostate cancer. In preliminary studies presented in this application, we also observed Tet, when injected to mice inhibited the growth of human prostate cancer xenografts in these mice, and dramatically decreased tumor volume. Tet inhibited Prostate Specific Antigen (PSA) synthesis and secretion, blocked cell cycle progression and growth of human PCa cells in culture, induced apoptosis, and inhibited cell migration and invasion, suggesting a direct effect of this compound on the neoplastic process. Based on these exciting preliminary data we hypothesize that "Tetrandrine (Tet) targets Androgen Receptor signaling to modulate multiple molecular events in PCa cells that are probably interrelated, such as PSA expression, cell survival and anti-apoptotic signaling and deregulated cell cycle progression involved in uncontrolled PCa growth and malignant progression." As such, Tet may serve as a novel agent for prevention, growth control and therapy of PCa. In the current proposal we will conduct basic and pre-clinical research on Tet with an aim to understand the mechanisms of action against prostate cancer. These objectives will be achieved in three Aims: Aim 1, is to evaluate the effects of Tet on modulation of Androgen Receptor signaling in prostate cancer cells and to study specific molecular mechanisms by which Tet inhibits Prostate Specific Antigen (PSA); Aim2, is to define, characterize, and establish molecular mechanism of the inhibitory effect of Tet on cell cycle progression and promotion of apoptosis in PCa cells.; Aim 3, is to evaluate efficacy of Tet against androgen responsive and castrate resistant human PCa cell derived mouse Xenograft models in vivo. We anticipate that proposed studies, together with our preliminary data, will identify Tet as a mechanism-based agent for the prevention, growth control and therapy of PCA, and will establish in vivo efficacy of Tet in pre-clinical human PCa cell derived xenograft models. It is important to emphasize here that an estimated 50,000 veterans being diagnosed with Prostate cancer every year and about 10,000 deaths result from prostate cancer in veteran population each year (based on Veterans Health education library and the National Prostate Cancer Coalition). Work proposed in this application, will contribute to development of a novel AR targeted therapy that may translate into an effective treatment regiment against prostate cancer and is therefore, highly relevant to Veteran health. PUBLIC HEALTH RELEVANCE: Prostate cancer (PCa) is the most common cancer diagnosed and the second leading cause of cancer death in men in the United States. Prostate cancer is the second most common cancer in veterans, with an estimated 50,000 veterans being diagnosed with prostate cancer every year. Prostate cancer results in about 10,000 deaths in veteran population each year and remains the second leading cause of cancer-associated deaths in veterans (based on Veterans Health education library and the National Prostate Cancer Coalition). In our exciting preliminary studies we discovered that Tetrandrine (Tet) selectively killed prostate cancer cells without harming normal cells, in part by targeting Androgen Receptor signaling. Work proposed in this application, will contribute to development of a novel AR targeted therapy that may translate into an effective treatment regiment against prostate cancer and is therefore, highly relevant to Veteran health.

描述（由申请人提供）：